Supernus to Present at March Cowen Health Care Conference
March 09 2016 - 7:46PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system diseases,
today announced that the Company's management will present an
overview and update of the Company and host investor meetings at
the Cowen & Company 36th Annual Health Care Conference.
Date: Monday, March 7, 2016Time: 2:40 p.m. ETPlace:
The Boston Marriott Copley Place, Boston, MA
Investors interested in arranging a meeting with
the Company's management during this conference should contact the
conference coordinator.
A live webcast of the presentation can be accessed
by visiting ‘Events & Presentations’ in the Investors Section
on the Company's website at www.supernus.com. An archived replay of
the webcast will be available for 60 days on the Company's website
after the conference.
About Supernus Pharmaceuticals,
Inc.
Supernus Pharmaceuticals, Inc. is a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system diseases. The
Company has two marketed products for epilepsy, Oxtellar XR®
(extended-release oxcarbazepine) and Trokendi XR® (extended-release
topiramate). The Company is also developing several product
candidates to address large market opportunities in psychiatry,
including SPN-810 for the treatment of impulsive aggression in
patients with ADHD. SPN-812 is being developed for treatment of
ADHD.
CONTACT:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Or
Investor Contact:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024